19446--10/15/2007--CANTEL_MEDICAL

related topics

{product, market, service}

{product, liability, claim}

{customer, product, revenue}

{personnel, key, retain}

{operation, international, foreign}

{cost, regulation, environmental}

{property, intellectual, protect}

{acquisition, growth, future}

{stock, price, share}

The consolidation of dialysis providers has resulted in greater buying power by certain of our customers, which has caused us to reduce the average selling prices of our dialysis products, thereby reducing net sales and profit margins. Such consolidation has also resulted in the loss of dialysate concentrate sales. Because a significant portion of our Healthcare Disposables segment net sales comes from a few large customers, any significant decrease in sales to these customers, due to industry consolidation or otherwise, could harm our operating results. The consolidation of distributors in the dental industry could result in a reduction in our net sales due to reduced average selling prices of our healthcare disposable products and the loss of private label business. The acquisition of new businesses and product lines, which has inherent risks, is an important part of our growth strategy. Our market for dialysis reprocessing products is limited to dialysis centers that reuse dialyzers, which market has been decreasing in the United States. In fiscal 2007, we commenced sales and service of our Medivators endoscope reprocessing systems in the United States on a direct basis. There can be no assurance that our direct sales and service program will be successful on a long term basis or that the future operating results of our Endoscope Reprocessing segment will return to historical levels. Competition from manufacturing facilities located in China could result in a reduction in our net sales of healthcare disposable products due to reduced average selling prices or our customers no longer purchasing certain products from us. We are subject to extensive government regulation. Government regulation may delay or prevent new product introduction. Customer acceptance of our products is dependent on our ability to meet changing requirements. We distribute our products in highly competitive markets. Currency fluctuations and trade barriers could adversely affect our results of operations. Certain of our businesses are heavily reliant on certain raw materials. Because we operate in international markets, we are subject to political and economic risks that we do not face in the United States. The markets for many of our products are subject to changing technology. We may be exposed to product liability claims resulting from the use of products we sell and distribute. We use chemicals and other regulated substances in the manufacturing of our products. We rely on intellectual property and proprietary rights to maintain our competitive position. If we are unable to retain key personnel, our business could be adversely affected. Our stock price has been volatile and may experience continued significant price and volume fluctuations in the future that could reduce the value of outstanding shares.

Full 10-K form ▸

19446--10/15/2007--CANTEL_MEDICAL_CORP